GPhA OUTLINES AGENDA FOR NEW FDA COMMISSIONER

Published Online: Saturday, July 1, 2006

Officials at the Generic Pharmaceutical Association (GPhA) are wasting no time in letting incoming FDA Commissioner Andrew von Eschenbach, MD, know what they will be expecting from him. In a statement welcoming Dr. von Eschenbach to the FDA, GPhA President and Chief Executive Officer Kathleen Jaeger said that the appointment of "a permanent commissioner is an absolute necessity at a federal agency that has such a direct impact on the health and well-being of America's citizens."

Jaeger urged the new FDA chief to move quickly "to appropriately address important issues, such as an abbreviated approval pathway for generic biopharmaceuticals, authorized generics, the timely approval of generic medicines, and increased funding for the Office of Generic Drugs."




Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A